The Solution

Calcipotriol

The substance in Daivonex® - the current leading non-steroidal topical drug -

Nicotinamide

 vitamin B3, demonstrating therapeutic properties

Effective Treatment

Clinical Data

Pipe Line

DPS-101, our leading product, has been developed through a comprehensive research and clinical development and is poised to answer the unmet need for safe and effective treatment for psoriasis. We are now initiating DPS-101 phase II/III clinical trial.

Nextgen holds a number of strong patent families protecting the various uses of DPS-101, as well as further medical and cosmetic applications based on our technology.

IP

DPS-101 is a novel, first of its kind topical treatment for psoriasis. Based on our previous clinical results, DPS-101 meets the need of effective, yet safe topical treatment. DPS-101 demonstrated higher efficiency than daivonex, today’ most used topical treatment, while no adverse effects were observed.

About

Science

Product

Investors

The Solution

DPS101

Clinical data

Pipe Line

IP